Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Rhea-AI Summary

Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on developing innovative therapies for retinal diseases and other eye conditions, has announced its plans to host a conference call and webcast on August 7, 2024, at 8:00 AM ET. The event will cover recent business progress and financial results for the second quarter ended June 30, 2024.

Participants can join the call using the following details:

• U.S. Dial-In: 1 (800) 343-4136
• International Dial-in: 1 (203) 518-9843
• Conference ID: OCULAR

A live and archived webcast will be available on the company's website in the Events and Presentations section of the Investor Relations page. The webcast replay will be accessible for 90 days after the event.

Conference call and webcast to begin at 8:00 AM ET

BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024.

Conference Call and Webcast Information:
Date: Wednesday, August 7, 2024, at 8:00 AM ET
Participant Dial-In (U.S.): 1 (800) 343-4136
Participant Dial-in (International): 1 (203) 518-9843
Conference ID: OCULAR
Webcast Access: Please click here

The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for 90 days.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn or X.

The Ocular Therapeutix logo and DEXTENZA^® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media

Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

When will Ocular Therapeutix (OCUL) report its Q2 2024 financial results?

Ocular Therapeutix (OCUL) will report its Q2 2024 financial results on August 7, 2024, during a conference call and webcast scheduled for 8:00 AM ET.

How can investors access Ocular Therapeutix's (OCUL) Q2 2024 earnings call?

Investors can access Ocular Therapeutix's (OCUL) Q2 2024 earnings call by dialing 1 (800) 343-4136 (U.S.) or 1 (203) 518-9843 (International) with the Conference ID: OCULAR. A webcast will also be available on the company's website.

What period will Ocular Therapeutix's (OCUL) Q2 2024 financial results cover?

Ocular Therapeutix's (OCUL) Q2 2024 financial results will cover the second quarter ended June 30, 2024.

How long will the webcast replay of Ocular Therapeutix's (OCUL) Q2 2024 earnings call be available?

The webcast replay of Ocular Therapeutix's (OCUL) Q2 2024 earnings call will be archived and available for 90 days after the event on the company's website.